Alnylam Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how the company is performing financially each quarter, helping you track growth or problems.
New board members bring expertise and help oversee the company's strategy and decisions.
Shows how companies reward leaders to keep them focused on long-term success and growth.
Shows how the company is performing financially each quarter, helping you track growth or problems.
Breaking even and launching new medicines show the company is executing its business plan successfully.
Annual results show total yearly performance, profitability, and whether long-term goals are being met.
Stocky reads Alnylam Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Alnylam Pharmaceuticals, Inc.'s most recent tracked filing was a 10-Q on 30 Jul 2026: Alnylam reports second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.